Autoimmune disease induced by dendritic cell immunization against leukemia

Area of Science:

• Immunology
• Cancer Research
• Immunotherapy

Background:

• Successful leukemia immunotherapy requires optimal immune responses.
• Dendritic cells (DC) and transgenic expression of CD40 ligand (gp39/CD154) and interleukin 2 (IL2) can augment immune responsiveness.

Purpose of the Study:

• To investigate if combining DC, CD40 ligand, and IL2 safely enhances anti-tumor immune responses against leukemia compared to individual stimuli.
• To assess the efficacy and safety of this combined immunotherapy approach.

Main Methods:

• BALB/CBYJ mice were injected with syngeneic DC pulsed with A20 lymphoblastic leukemia cell antigens.
• Pulsed DC were combined with genetically modified fibroblasts expressing CD40 ligand or secreting IL2.
• Mice were vaccinated weekly and challenged with A20 cells to evaluate tumor growth and survival.

Main Results:

• Pulsed DC alone suppressed tumor growth (P < 0.02).
• Combined DC, CD40 ligand, and IL2 significantly enhanced tumor suppression (P < 0.0005 vs. DC alone), leading to long-term tumor-free survivors.
• This intensive stimulation also induced severe systemic autoimmune disorders resembling graft-versus-host disease, mediated by CD8+ cytotoxic T lymphocytes.

Conclusions:

• Combined immunotherapy with DC, CD40 ligand, and IL2 is highly effective in eradicating leukemia in a mouse model.
• This potent immune stimulation can lead to a loss of self-tolerance and induce severe anti-self autoimmune responses.
• Future leukemia immunotherapies must balance anti-tumor efficacy with the risk of autoimmunity.